We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+17.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.6B
AUM Growth
+$255M
Cap. Flow
-$1.97M
Cap. Flow %
-0.08%
Top 10 Hldgs %
27.03%
Holding
158
New
8
Increased
60
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$19.4M
2
UNH icon
UnitedHealth
UNH
+$19.2M
3
WST icon
West Pharmaceutical
WST
+$14.7M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$12.2M
5
ARGX icon
argenx
ARGX
+$11.5M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.1M
2
AET
Aetna Inc
AET
+$40.4M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.5M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$9.19M
5
ZTS icon
Zoetis
ZTS
+$8.44M

Sector Composition

Rank Sector Weight
1 Healthcare 89.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$382B
$139M 5.36%
567,500
+80,000
+16% +$19.2M
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.6B
$95.7M 3.68%
342,300
+16,800
+5% +$2.95M
ISRG icon
3
Intuitive Surgical
ISRG
$127B
$67.9M 2.61%
425,700
-6,000
-1% -$915K
NBIX icon
4
Neurocrine Biosciences
NBIX
$18.2B
$61.9M 2.38%
630,400
+24,200
+4% +$2.17M
GWPH
5
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$61.4M 2.36%
440,000
+80,000
+22% +$11.4M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$61.1M 2.35%
492,500
+7,500
+2% +$877K
ABBV icon
7
AbbVie
ABBV
$465B
$55.6M 2.14%
600,000
– –
WCG
8
DELISTED
Wellcare Health Plans, Inc.
WCG
$54.9M 2.11%
223,000
+89,000
+66% +$19.4M
MOH icon
9
Molina Healthcare
MOH
$10.4B
$53.4M 2.05%
545,000
-31,000
-5% -$2.7M
ACHC icon
10
Acadia Healthcare
ACHC
$2.52B
$51.3M 1.97%
1,253,500
– –
LOXO
11
DELISTED
Loxo Oncology, Inc
LOXO
$50.3M 1.94%
289,900
-26,600
-8% -$4M
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$45M 1.73%
544,000
-79,500
-13% -$6.14M
HCA icon
13
HCA Healthcare
HCA
$90.6B
$44.1M 1.7%
430,000
+50,000
+13% +$5.06M
COLL icon
14
Collegium Pharmaceutical
COLL
$1.18B
$39.4M 1.51%
1,650,000
-270,000
-14% -$6.64M
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.64B
$39.3M 1.51%
297,500
+39,500
+15% +$3.73M
IRTC icon
16
iRhythm Holdings
IRTC
$4.02B
$38.9M 1.5%
480,000
+2,500
+0.5% +$175K
PCRX icon
17
Pacira BioSciences
PCRX
$1.04B
$38.4M 1.48%
1,198,000
+73,000
+6% +$2.52M
RDUS
18
DELISTED
Radius Health, Inc.
RDUS
$33.2M 1.28%
1,125,000
+125,000
+13% +$3.95M
ONC
19
BeOne Medicines Ltd
ONC
$33.9B
$33.1M 1.27%
215,000
-6,250
-3% -$1.11M
PEN icon
20
Penumbra
PEN
$12.6B
$32.7M 1.26%
236,750
-6,250
-3% -$890K
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$123B
$32.4M 1.25%
190,500
+9,500
+5% +$1.47M
EHC icon
22
Encompass Health
EHC
$11.3B
$30.5M 1.17%
565,650
+154,611
+38% +$7.73M
SYK icon
23
Stryker
SYK
$135B
$30.1M 1.16%
178,000
– –
CELG
24
DELISTED
Celgene Corp
CELG
$28.6M 1.1%
360,400
+50,300
+16% +$4.18M
DVA icon
25
DaVita
DVA
$15.5B
$28.4M 1.09%
408,500
+1,000
+0.2% +$66.8K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rock Springs Capital Management held 158 positions worth $2.6B, up 11% from $2.34B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q2 2018 filing shows 8 new, 60 increased, 24 reduced and 11 closed positions. Its largest new stake was West Pharmaceutical: 160,000 shares worth $15.9M. The largest sale was Bristol-Myers Squibb, an estimated $41.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Financials.

  • Rock Springs Capital Management's largest Q2 2018 buy was West Pharmaceutical: 160,000 shares worth $15.9M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q2 2018, an estimated $19.4M increase.
  • Rock Springs Capital Management's biggest Q2 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $9.19M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $41.1M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $2.6B portfolio in Q2 2018.
  • Rock Springs Capital Management opened 8 new positions and closed 11 in Q2 2018.
  • Rock Springs Capital Management's portfolio value rose 11% quarter-over-quarter to $2.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.